Echium

Echium: A Comprehensive Reference

1. Identity, Taxonomy, and Botanical Description

Genus and family: Echium L. is a genus of flowering plants belonging to the family Boraginaceae. The genus consists of 67 recognised species, which are native to North Africa, mainland Europe, and the Macaronesia region (the Azores, Madeira, Canary Islands, and Cape Verde), where they are found to be annual, biennial, or perennial flowering plants. Interestingly, 70% of species endemic to the Macaronesian archipelagos are found to be woody shrubs, while continental species are mostly herbaceous.

Principal species of commercial and medicinal interest include:

• Echium plantagineum L. (Purple Viper's Bugloss; Paterson's Curse) — the primary commercial source of echium seed oil for nutraceutical use.
• Echium vulgare L. (Common Viper's Bugloss) — the most frequently studied species, potentially linked to its broader geographic distribution and well-documented bioactive compound profiles.
• Echium amoenum Fisch. & C.A.Mey. — an Iranian species extensively studied for mood-related effects.
• Echium italicum L. and Echium russicum J.F. Gmel. — additional medicinal species found in Eastern Europe.

Echium plantagineum is a winter annual native to Mediterranean Europe and North Africa. Commonly known as "Purple Viper's Bugloss" or "Paterson's Curse," it was introduced as an ornamental in Australia and the U.S.A. during the 1800s. Over time, it has become known as a weedy, invasive species, notorious for its impact on natural habitats and agricultural lands.

2. Common Forms and Preparations

Echium species have been applied for treating wounds, urinary tract infections, inflammation, respiratory ailments, cardiovascular disorders, and microbial infections. The roots and flowers are most frequently used, typically prepared as decoctions or infusions.

In modern nutraceutical and supplement contexts, Echium plantagineum seed oil is the primary commercially distributed form. Echium oil is a vegetable oil of non-GMO plant origin extracted from the seeds of Echium plantagineum containing significant amounts of omega-3 fatty acid stearidonic acid (SDA) and omega-6 acid γ-linolenic acid (GLA). Refined echium seed oil has been authorized as a novel food ingredient for human consumption, but the use of virgin, cold-pressed oil is still restricted in the EU. Although it is considered an excellent source of ω-3 fatty acids, the great proportion of polyunsaturated fatty acids (>70%) in echium seed oil makes it highly susceptible to oxidation.

Echium oil is an approved novel food in the European Union, with SDA content required at 10% or more of the total fatty acid content. It is permitted for use in a range of general-purpose foods including milk, yoghurt, cheese, spreadable fats, and breakfast cereals.

For the E. amoenum flower preparations used in traditional and clinical contexts, the plant is prepared as an aqueous extract (infusion or decoction). The plant is traditionally either brewed or boiled in water before drinking.

3. Traditional and Historical Use

The ethnomedicinal history of the Echium species can be traced back to 300 B.C. in the Mediterranean area. Reports indicate various species have been used as folk medicine in the region, utilised predominately for their sedative, anti-inflammatory, antioxidant, and anxiolytic properties, treating ailments including fissures of the hands, general abrasions, and even snakebites.

The species are widely distributed around the Mediterranean basin, Europe, and the Macaronesian Islands and are known for their analgesic, diuretic, antioxidant, antimicrobial, and antitumor properties. In traditional medicine, they are widely used as a wound-healing and anti-inflammatory agent, for respiratory problems and problems related to mental health, and for general abrasions and fissures of the hands.

Echium vulgare L. and Echium plantagineum L. originated in the Mediterranean, and were later domesticated in Africa, America, Asia, Europe, and Oceania, where they were widely used to treat many diseases including cough, urinary tract infection, fever, inflammation, and muscle strain.

Turkish ethnomedicine: The root of E. angustifolium and the herbs of E. parviflorum, E. plantagineum, and E. russicum have been reportedly used in Turkish traditional medicine. The aerial parts of E. plantagineum are locally known as 'Engerek ut,' and its decoction is prepared as a tea with diaphoretic and diuretic effects. A traditional ethnobotanical study conducted in Bilecik Province, Turkey, identified E. plantagineum as a widely used medicinal plant for treating infections and skin disorders.

Middle Eastern and North African traditions: In Jordan, E. glomeratum (locally known as 'Sag Al-hamam') is said to possess analgesic, diaphoretic, and aphrodisiac effects and has been used for the treatment of snake bites. E. judaeum ('Lesan Al-Thoor') has also been used in the Jordanian provinces for its sedative effects, managing hyperactivity, and anxiety.

Iranian traditional medicine: Echium amoenum is an Iranian medicinal plant with mood-enhancing effects. All parts of the plant including stems, leaves, and flowers, except for the root, have medicinal applications. Persian Echium amoenum is used for relaxation and mood improvement, as well as the treatment of sore throat, pneumonia, and cough.

Medieval European use: In medieval Europe, it was believed to protect against viper bites, hence the name "Viper's Bugloss." It was also used in potions and traditional medicine. Historically, it was used in folk remedies for respiratory issues and as a poultice for minor wounds.

4. Key Constituents and Active Compounds

Phytochemical studies have identified diverse bioactive compounds, including phenolics, naphthoquinones, shikonins, fatty acids, sterols, terpenoids, amino acids, and toxic pyrrolizidine alkaloids.

4.1 Fatty Acids (Seed Oil)

The fatty acid composition of Echium plantagineum seed oil makes it botanically unique among plant oils. Typical fatty acid composition of Echium oil is: oleic acid (18:1 n-9) 16%, linoleic acid (LA, 18:2 n-6) 19%, γ-linolenic acid (GLA, 18:3 n-6) 10%, α-linolenic acid (ALA, 18:3 n-3) 30%, and stearidonic acid (SDA, 18:4 n-3) 13%.

Stearidonic acid (SDA, C18:4 n-3) is the most pharmacologically distinctive constituent. Echium (Echium plantagineum) represents a potential alternative for human supplementation, belonging to the Boraginaceae family and being rich in stearidonic acid (SDA, 18:4 n-3), which bypasses the rate-limiting Δ6-desaturation step in the n-3 FA biosynthetic pathway, thereby enhancing the conversion efficiency to EPA and DHA when compared with ALA.

Gamma-linolenic acid (GLA, C18:3 n-6) is an omega-6 fatty acid also present in meaningful quantities. GLA is commonly associated with the anti-inflammatory effects of oils such as evening primrose oil and borage oil. Supplementation with GLA can markedly increase serum arachidonic acid (AA) with subsequent pro-inflammatory effects. Uniquely, however, the presence of stearidonic acid in echium oil prevents the accumulation of serum AA and AA-derived eicosanoids without preventing the accumulation of DGLA, which is the real n-6 precursor of anti-inflammatory eicosanoids.

4.2 Phenolic Compounds and Flavonoids

One of the best-characterised compounds isolated from the Echium genus is rosmarinic acid, which is found in several Echium species, such as E. amoenum, E. russicum, and E. vulgare. When extracted with hot water, E. amoenum petals were shown to have the highest content of rosmarinic acid within these species.

Nineteen flavonoids have been identified in various species, including kaempferol, peonidin, cyanidin, malvidin, and their monoglucoside or disaccharide C3-linked derivatives, with kaempferol-3-O-neohesperidoside found to be the major constituent. Other phenolic acids have been well characterised in E. russicum, including salvianolic acid A, rabdosiin, lithospermic acid, and eritrichin (globoidnan A).

Notable compounds such as luteolin-7-O-glucoside, kaempferol-3-O-neohesperidoside, and rosmarinic acid exhibit a broad spectrum of pharmacological effects, including antioxidant, anti-inflammatory, neuroprotective, and antimicrobial activities.

4.3 Naphthoquinones: Alkanins and Shikonins

The roots of several Echium species are particularly enriched with alkanins and shikonins, naphthoquinone compounds with well-documented wound-healing, collagen-stimulating, and anticancer properties. Shikonins are major naphthoquinone secondary metabolites of Echium species that have been studied for their wound-healing, anti-inflammatory, and antimicrobial activities.

4.4 Volatile Constituents

Volatile constituents such as thymol, carvacrol, and pulegone contribute further to the antimicrobial and antifungal potential of these plants.

4.5 Pyrrolizidine Alkaloids (PAs)

Pyrrolizidine alkaloids (PA) are secondary metabolites of plants, which are mostly found in the genus Senecio, Echium, Crotalaria, and Eupatorium. PAs exhibit developmental toxicity and have been shown to be hepatotoxic, pneumotoxic, genotoxic, and carcinogenic. Their presence in Echium is a key safety concern (discussed further in Section 8).

4.6 Additional Constituents

The aqueous flower extract of E. amoenum contains flavonoids, saponins, unsaturated terpenoids, and sterols. The seed oil of E. amoenum, rich in alpha-linolenic acid (ALA), highlights the genus's relevance in pharmaceutical, nutraceutical, and cosmeceutical applications.

5. Established Mechanisms of Action

5.1 SDA as an EPA Precursor — Bypassing the Rate-Limiting Step

The primary documented mechanism distinguishing echium oil from other plant-based omega-3 sources relates to its SDA content. Studies have shown that ALA is poorly converted to EPA in humans and rodents (4–15% conversion efficiency), and the degree of conversion depends on the amount of linoleic acid (18:2) in the diet, since 18:2 competes with ALA for Δ6-desaturation and diminishes the conversion of ALA to EPA.

An approach that holds promise is to use a botanical oil that is enriched in SDA (18:4 n-3), which is the immediate product of Δ6-desaturation of ALA. Since Δ6-desaturase is the rate-limiting step in the formation of EPA from ALA, dietary supplementation with SDA can enrich cellular membranes and plasma lipoproteins with EPA and may result in the beneficial cardiovascular effects of fish oil.

In humans, the ability of SDA to increase EPA in blood is higher than that of ALA, presumably because it bypasses the rate-limiting Δ6-desaturase step. Multiple studies have shown that SDA is effectively converted to EPA by the liver, at around 25–30%.

5.2 Anti-inflammatory Mechanisms

The natural ratio of fatty acids in echium oil, through their metabolism, delivers enhanced plasma concentrations of eicosapentaenoic acid (EPA, 20:5 n-3), docosapentaenoic acid (DPA, 22:5 n-3), and dihomo-γ-linolenic acid (DGLA, 20:3 n-6) acids without increasing the concentrations of arachidonic acid (AA, 20:4 n-6).

SDA is believed to inhibit cyclooxygenase activity and thereby block the conversion of arachidonic acid to PGE2. In in vitro skin models, echium oil decreased PGE2 levels after UV exposure more than other oils applied, with this anti-inflammatory potential attributed to its levels of SDA.

In macrophage studies using E. amoenum extract, real-time PCR analysis indicated reduced levels of iNOS and COX-2 gene expressions with the 100 μg/mL hexane extract, and IL-1β, TNF-α, and IL-6 gene expression levels decreased at all concentrations of the extract. Treatment of LPS-stimulated cells with 100 μg/mL of the extract reduced IL-1β secretion to 27.9 ± 0.21 pg/mL and IL-6 to 555 ± 166 pg/mL.

5.3 Neurological / Mood-Related Mechanisms

Mechanisms expressed for the antidepressant effects of Echium amoenum include: (1) non-selective inhibition of reabsorption of serotonin, noradrenaline, and dopamine, which increases serotonergic and dopaminergic receptors; (2) increased affinity for gamma-aminobutyric acid (GABA) receptors; and (3) inhibition of monoamine oxidase activity. This plant may be effective on neurotransmitters like norepinephrine and serotonin, making it a potential therapeutic for treating depression.

6. Scientific Evidence by Health Area

6.1 Omega-3 Status and Cardiovascular Lipids

Evidence strength: Moderate (human RCT data available; DHA elevation remains limited).

In two double-blind, parallel-arm, randomized controlled studies, all volunteers started with 17 g/d run-in oil (2 weeks). Thereafter, subjects received diets enriched in study 1 with EO (5 g ALA + 2 g SDA; n = 59) or in study 2 with linseed oil (LO) (5 g ALA; n = 59) daily for 8 weeks. The smaller control groups received fish oil (FO; n = 19) or olive oil (OO; n = 18). Results suggest it is likely that echium oil may play a role in preventing progression of CVD and type 2 diabetes mellitus.

However, neither echium oil nor linseed oil maintained blood DHA status in the absence of fish/seafood consumption. This is an important limitation: echium oil increases EPA and DPA but does not reliably elevate DHA in humans.

In a separate human study using 15 g/day echium oil (estimated at 1.9 g/d SDA) in hypertriglyceridemic adults, treatments were provided as capsules. Echium oil, administered at 15 g/day (estimated to equate to 1.9 g/d SDA), was studied in hypertriglyceridemic adults.

Echium oil (EO), which is enriched in SDA (18:4 n-3), reduces plasma triglyceride (TG) concentrations in humans and mice. Animal model evidence supports this further: animals supplemented with Echium oil presented lower total cholesterol and triacylglycerol concentrations than control groups and lower VLDL than all of the other groups, constituting the best lipoprotein profile observed in one study. These results suggest that Echium oil represents an alternative as a natural ingredient to be applied in functional foods to reduce cardiovascular disease risk factors. However, these lipid-profile findings from animal models require confirmation in well-powered human RCTs.

An ongoing clinical trial registered at ClinicalTrials.gov (NCT07289919) will have fifteen participants undergo three 8-week intervention phases — Echium oil (15 g/day), Ahiflower oil (15 g/day), or EPA capsules (2.34 g/day) — separated by four-week washout periods. Blood samples will be collected before and after each phase to measure fatty acid profiles. The study seeks to determine whether SDA-rich plant oils can effectively increase EPA levels in humans and potentially reduce the reliance on marine oils for cardiovascular health benefits.

6.2 Mood Disorders: Depression

Evidence strength: Preliminary (small RCTs; replication needed).

Several small clinical trials have examined E. amoenum flower extract for depression.

In a pivotal early trial, the efficacy of an aqueous extract of E. amoenum in patients with mild to moderate major depressive disorder (a score ≥18 on the Hamilton depression rating scale) was evaluated. 35 patients were randomly assigned to receive daily either placebo or 375 mg of E. amoenum aqueous extract in a 6-week double-blind, parallel-group trial. Patients were assessed in weeks 0, 1, 2, 4, and 6 by the Hamilton Rating Scale for Depression (HAM-D17), the Hamilton Rating Scale for Anxiety (HAM-A14), and a score sheet on adverse effects. In week 4, the extract showed a significant superiority over placebo in reducing depressive symptoms. The effect on anxiety was not significant.

A subsequent combination trial examined E. amoenum alongside Hypericum perforatum: in an 8-week double-blind, parallel-group trial, 51 patients randomly consumed 20 mg of fluoxetine or 350 mg of herbal medicine twice daily. The Hamilton Rating Scale for Depression (HAM-D) was used to assess depression severity at weeks 0, 4, and 8. According to the Hamilton score, there were no significant differences between the fluoxetine- and herbal medicine-treated groups after 4 and 8 weeks (p>0.05). Dry mouth was the only reported side effect, which was significantly lower in the herbal group (p<0.05) in weeks 2 and 4.

Limitations: All identified clinical trials are small (n = 35–51), conducted primarily in Iran, and most focus on a combination product. Independent replication in larger, multi-centre populations is absent.

6.3 Anxiety Disorders

Evidence strength: Preliminary (single small RCT; animal data supportive).

The aim of one study was to assess the efficacy and tolerability of the aqueous extract of Echium amoenum in combination with SSRIs in patients with General Anxiety Disorder (GAD). The study was an 8-week double-blind randomized clinical trial. Thirty-seven adult outpatients who met the DSM-IV-TR criteria for GAD participated. Patients were randomly assigned to receive the aqueous extract (500 mg) plus fluoxetine or fluoxetine (20 mg/day) plus placebo. The results showed a significant difference between the two groups in the treatment of GAD. Moreover, there was not any significant difference between the two groups in terms of observed side effects. E. amoenum was reported as effective on anxiety disorder, especially in higher dosage, without any serious side effects.

In a smaller trial using a different preparation, the intervention group received 1 g Echium amoenum powder in 250cc boiling water daily for one month.

Animal-model evidence shows mice received E. amoenum extract (75, 150, and 300 mg/kg, p.o.) concomitantly with restraint stress exposure. Anxiety-like behaviors were assessed by Elevated Plus Maze (EPM) and Open Field Test (OFT), and depression was assessed by the forced swim test (FST) and Tail Suspension Test (TST).

Limitations: The anxiety RCT is small and used an add-on design (EO plus SSRI), making it impossible to isolate the effect of the extract alone. Preclinical data are from rodent models only.

6.4 Skin Health and Dermatological Applications

Evidence strength: Weak to preliminary (in vitro and small controlled studies; large-scale human clinical trials are lacking).

To date, large-scale clinical studies assessing the therapeutic effects of Echium species in humans have not been conducted; however, mechanistic data suggest that its oil could be effective for reducing skin inflammation. Current phytochemical and experimental evidence suggest potential health applications, although most findings remain preclinical and require further clinical validation.

Mechanistically, in vitro studies using skin substitutes show that to full skin substitutes containing human fibroblasts and keratinocytes, 3 µl each of echium oil, blackcurrant oil, borage oil, and marine oil were topically applied for 24 hours; one control sample was left untreated. Subsequently, the skin substitutes were exposed to UVB light at a dose of 4 J/cm², after which PGE2 levels were determined. The results demonstrated that echium oil decreased PGE2 levels after UV exposure more than the other oils applied.

PUFAs in echium seed oil, particularly SDA, ALA, and GLA, maintain epidermal barrier integrity by supporting lipid structure within the stratum corneum.

Scientific evidence supporting Echium for skin health is limited. Some studies on Echium oil (notably Echium plantagineum seed oil) highlight its high content of omega-3 and omega-6 fatty acids, such as stearidonic acid and gamma-linolenic acid, which are known to support skin barrier function and reduce inflammation. However, direct clinical studies assessing Echium preparations for specific skin conditions in humans are sparse. While traditional use of Echium for skin health is documented and there is some theoretical scientific basis due to its fatty acid profile, high-quality evidence from controlled human studies is lacking.

6.5 Antioxidant Activity

Evidence strength: In vitro only; no meaningful human clinical evidence.

Current pharmacological studies have validated early ethnomedicinal properties showing that Echium spp. possesses antioxidant, analgesic, anxiolytic, anti-inflammatory, antibacterial, and antiviral effects. These findings are predominantly from cell and animal models, and should not be interpreted as established human efficacy.

6.6 Antimicrobial and Cytotoxic Activity

Evidence strength: Preliminary in vitro only.

Methanolic extracts derived from the roots, flowers, and leaves of E. serbicum exhibit selective cytotoxicity against various cancer cell lines, including HCT-116, SW-480, MDA-MB-231, and normal MRC-5 cells. Reported pharmacological effects include antioxidant, antimicrobial, and cytotoxic activities, primarily attributed to polyphenolic and terpenoid content. These findings are in vitro only and have not been studied in human clinical trials.

6.7 Potential Applications in Inflammatory and Autoimmune Conditions

Evidence strength: Theoretical and animal-model based only.

The omega-3 long-chain polyunsaturated fatty acids rich in Echium oil may have beneficial effects on inflammatory and autoimmune diseases such as atherosclerosis, rheumatoid arthritis, asthma, and Alzheimer's disease. Echium oil has many potential uses in the pharmaceutical industry, and may be used to treat eczema, acne, and other skin diseases. These statements represent mechanistic hypotheses rather than verified clinical findings.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported as they appear in identified sources and are not recommendations:

• Echium seed oil (oral, for fatty acid status): 5 g ALA + 2 g SDA from echium oil daily for 8 weeks (in a randomized controlled study, n = 59).
• Echium seed oil (oral, in hypertriglyceridemic adults): 15 g/day echium oil, estimated to equate to 1.9 g/d SDA, provided as capsules.
• Echium oil (topical, skin research): 3 µl applied topically to full skin substitutes for 24 hours in in vitro UVB studies.
• E. amoenum aqueous extract (for depression): 375 mg of E. amoenum aqueous extract daily in a 6-week double-blind trial (n = 35).
• E. amoenum combined extract (for depression vs. fluoxetine): 350 mg of herbal medicine (combined E. amoenum and H. perforatum) twice daily for 8 weeks (n = 51).
• E. amoenum aqueous extract (for GAD): 500 mg of the aqueous extract plus fluoxetine in an 8-week double-blind trial (n = 37).
• E. amoenum powder (for anxiety in students): 1 g Echium amoenum powder in 250cc boiling water daily for one month.
• Animal studies (E. amoenum extract): Doses of 75, 150, and 300 mg/kg p.o. in mice in restraint-stress models.

8. Safety Considerations and Interactions

8.1 Pyrrolizidine Alkaloids — The Central Safety Concern

The presence of pyrrolizidine alkaloid (PA) toxic compounds associated with hepatotoxicity remains a critical safety concern in Echium. PAs exhibit developmental toxicity and have been shown to be hepatotoxic, pneumotoxic, genotoxic, and carcinogenic.

Pyrrolizidine alkaloids (PAs) are toxic compounds widespread throughout the plant kingdom, occurring in about 3% of flowering plants. Over 350 PAs have been identified so far. The plants containing PAs belong mainly to the Asteraceae (Senecioneae and Eupatorieae tribes), Boraginaceae (all genera), and Fabaceae (genus Crotalaria). PAs occur as free-base/tertiary forms or their N-oxides, and both forms are hepatotoxic and genotoxic.

Specific to Echium plantagineum, alkaloids including echimidine are present. In rat hepatocyte primary culture cells, the alkaloids at 3 to 300 µg/mL caused concentration-dependent inhibition of hepatocyte viability with mean IC₅₀ values ranging from 9.26 to 14.14 µg/mL.

The toxicity of PAs depends mainly on the nature of the bond in position 1,2 of the pyrrolizidine ring system. The toxicity of PAs in humans is well known from various poisoning cases following ingestion of PA-containing herbal medicines and teas. The available information indicates that the adverse effects of 1,2-unsaturated PAs in experimental animals include hepatotoxicity, developmental toxicity, genotoxicity, and carcinogenicity.

8.2 Regulatory Position on PAs

In 2020, the European Food Safety Authority (EFSA) updated the risk characterization and identified a reference point of 237 μg PA/kg body weight per day for the sum of all PAs ingested, assuming that all structurally diverse PAs have an equal toxic potency with riddelliine, a representative toxic PA which induces liver hemangiosarcoma in female rats.

The WHO, BfR, EMA, and UK Toxicity Committee have established acceptable daily intake for total PAs. The European Union officially announced a total limit of 150 μg/kg for PAs in teas and flavored teas (CR (EU) 2023/915 amending regulation (EC) 1881/2006).

EFSA noted that the plant itself contains active substances such as pyrrolizidine alkaloids, but that the refining process reduced these levels to below the maximum limits set in the EU. The EU novel food authorization for refined echium seed oil was therefore contingent on the refining process adequately eliminating PAs. Unrefined or cold-pressed echium oil has not received the same authorization.

8.3 Oxidative Stability

Although echium seed oil is considered an excellent source of ω-3 fatty acids, the great proportion of polyunsaturated fatty acids (>70%) in its composition makes it highly susceptible to oxidation. Oxidation can result in the formation of secondary lipid peroxidation products and degradation of bioactive fatty acids, making proper storage and stabilization of echium oil preparations an important quality consideration.

8.4 DHA Limitation

Neither echium oil nor linseed oil maintained blood DHA status in the absence of fish/seafood consumption. This means echium oil cannot serve as a complete substitute for long-chain omega-3 supplementation where DHA is the therapeutic target (e.g., neurological conditions, certain cardiovascular indications).

8.5 Veterinary Toxicity (Livestock)

Echium plantagineum, as an invasive weed in Australia, is known to cause livestock toxicity, principally in sheep and cattle, through PA accumulation leading to a condition called "Kimberley horse disease" or "Walkabout disease." This is a well-established veterinary hazard attributable to the same PA chemistry discussed above, though it does not directly translate to acute risk at supplemental doses in humans using refined seed oil products that comply with PA specifications.

8.6 Potential Interaction Considerations

Evidence supports traditional medicinal uses and highlights diverse bioactive constituents with therapeutic effects against inflammation, oxidative stress, skin disorders, anxiety, and cancer. However, the presence of toxic pyrrolizidine PAs necessitates rigorous safety evaluations. Given that E. amoenum extracts have been tested alongside SSRIs (fluoxetine), subjects with psychotic symptoms, suicidal thoughts, any other psychiatric or neurological disorder, significant cardiac, renal, or hepatic diseases, pregnancy, or lactation were excluded from clinical trials. This exclusion profile reflects the known hepatotoxic potential of PAs and the pharmacological activity of the flavonoid-rich extracts.

9. Body Systems and Health Areas Associated with Echium

• Cardiovascular system: Triglyceride reduction; EPA enrichment of plasma and red blood cell membranes; preliminary evidence in humans for improved lipid profiles.
• Central nervous system: E. amoenum extracts studied for depression and anxiety via serotonergic, noradrenergic, dopaminergic, GABAergic, and MAO-inhibitory mechanisms.
• Integumentary system (skin): Barrier support via PUFA incorporation; in vitro reduction of UV-induced PGE2 and pro-inflammatory mediators; naphthoquinone compounds (shikonin/alkanin) with wound-healing properties.
• Immune and inflammatory systems: Modulation of eicosanoid pathways; downregulation of IL-1β, IL-6, TNF-α, COX-2 in preclinical models.
• Hepatic: Hepatoprotective effects suggested by animal models of hepatic steatosis; also the primary organ of risk from PA toxicity.
• Respiratory: Traditional use for cough, respiratory ailments; limited modern scientific evidence.
• Antimicrobial: In vitro evidence against bacterial and fungal pathogens; no human clinical evidence.

References

• Genus Echium L.: Phytochemical Characterization and Bioactivity Evaluation for Drug Discovery — PMC (Plants, 2025)
• A Review of the Main Biologically Active Compounds of the Genus Echium L., Naturally Distributed in Bulgaria, and Their Pharmacological Potential — PMC (Pharmaceuticals, 2025)
• Antioxidant Properties and Reported Ethnomedicinal Use of the Genus Echium (Boraginaceae) — PMC (Antioxidants, 2020)
• Consumption of Echium Oil Increases EPA and DPA in Blood Fractions More Efficiently Compared to Linseed Oil in Humans — PMC (Lipids in Health and Disease, 2016)
• Echium Oil Reduces Plasma Lipids and Hepatic Lipogenic Gene Expression in apoB100-only LDL Receptor Knockout Mice — PMC
• Effect of Echium Oil Compared with Marine Oils on Lipid Profile and Inhibition of Hepatic Steatosis in LDLr Knockout Mice — PMC (Lipids in Health and Disease, 2013)
• Echium Oil Reduces Plasma Triglycerides by Increasing Intravascular Lipolysis in apoB100-Only LDL Receptor Knockout Mice — Nutrients (MDPI, 2013)
• A Double-Blind, Placebo-Controlled Study of the Aqueous Extract of Echium amoenum for Patients with General Anxiety Disorder — PMC
• A Preliminary Randomized Double Blind Clinical Trial on the Efficacy of Aqueous Extract of Echium amoenum in the Treatment of Mild to Moderate Major Depression — Progress in Neuro-Psychopharmacology & Biological Psychiatry (2006)
• The Antidepressant Effect of Combined Extracts of Hypericum perforatum and Echium amoenum Supplementation in Patients with Depression Symptoms: A Randomized Clinical Trial — PMC
• Isolation of Echimidine and Its C-7 Isomers from Echium plantagineum L. and Their Hepatotoxic Effect on Rat Hepatocytes — PMC
• Anti-inflammatory Activity of Echium amoenum Extract on Macrophages Mediated by Inhibition of Inflammatory Mediators and Cytokines Expression — PMC
• Dietary Exposure Assessment to Pyrrolizidine Alkaloids in the European Population — EFSA Journal (2016)
• Levels, Toxic Effects, and Risk Assessment of Pyrrolizidine Alkaloids in Foods: A Review — PMC
• Eicosapentaenoic and Docosahexaenoic Acid Levels in Mouse Tissues After Intake of Echium and Ahiflower Oils Rich in Stearidonic and α-Linolenic Acids — Lipids (2026)
• Echium Oil: A Valuable Source of n-3 and n-6 Fatty Acids — OCL Journal (2008)
• Risk Assessment of Pyrrolizidine Alkaloids in Food of Plant and Animal Origin — Food and Chemical Toxicology (2018)
• Oral and Topical Echium Oil for Skin Benefits — Cosmetics & Toiletries
• Why Echium Seed Oil Is Emerging as a Potential Plant-Based Alternative to Fish Oil — News-Medical (2026)
• Exploring Sustainable Alternatives to Marine Oils With Echium and Ahiflower Oils — ClinicalTrials.gov
• New Seed Oils of Boraginaceae Rich in Stearidonic and Gamma-Linolenic Acids from the Maghreb Region — Journal of Food Composition and Analysis (2013)
• Antidepressant and Anxiolytic Effect of Echium amoenum in Restraint Stress Model: The Role of Neuroinflammation in the Prefrontal Cortex and Hippocampus — Iranian Red Crescent Medical Journal (2019)